The FDA has approved a subcutaneous formulation of Eisai and Biogen’s Alzheimer's therapy Leqembi, facilitating easier administration that could enhance patient adherence compared to the intravenous version. This approval marks a strategic step in positioning the drug more competitively in the growing Alzheimer's therapeutics market. The new formulation can be administered under the skin while maintaining the efficacy of the original treatment.